FDA Investigates Tumor Risk in Novartis' Zolgensma Gene Therapy

The U.S. Food and Drug Administration (FDA) has scrutinized the tumor risk associated with the gene therapy Zolgensma, used in the treatment of spinal muscular atrophy. In a statement by Novartis, it was noted that a total of nine cases have been reported since 2019. The company announced that genetic findings related to the treatment were detected in two of these cases. The FDA's review has reignited questions about the long-term safety profile of gene therapies. Zolgensma is known as a gene therapy used in the treatment of spinal muscular atrophy. The cases reported by Novartis have drawn the attention of regulatory agencies regarding possible side effects of the treatment. The results of the FDA's review and potential regulatory steps are being closely followed for safety assessments in the field of gene therapy. Not investment advice.

📊 NVS — Piyasa Yorumu

▼ down · 55%

The FDA's review of tumor risk in the Zolgensma gene therapy may create near-term uncertainty and negative news flow for Novartis. At the last close, the price was 162.53, slightly below the SMA20 (163.32) and under the MACD signal line, indicating weak momentum. The RSI is 51.7, in neutral territory; there is no oversold support, which leaves room for news-driven selling pressure. However, the review is not yet a sanction or product withdrawal, so the impact may remain limited. I expect mild downward pressure over the next 1-3 days; a sharp decline would require additional negative developments.

RSI 14

51.7

MACD

0.24

24h Δ

1.59%

Canlı Grafikler